Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | dopamine receptor D3 | Starlite/ChEMBL | No references |
Homo sapiens | dopamine receptor D2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | hypothetical protein | dopamine receptor D3 | 400 aa | 392 aa | 19.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tar DNA-binding protein | 0.0074 | 0.3239 | 0.2987 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 1 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0021 | 0.0359 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0051 | 0.1944 | 0.1644 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0074 | 0.3239 | 0.2987 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0021 | 0.0359 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0074 | 0.3239 | 0.2987 |
Echinococcus granulosus | tar DNA binding protein | 0.0074 | 0.3239 | 0.2987 |
Schistosoma mansoni | tar DNA-binding protein | 0.0074 | 0.3239 | 0.2987 |
Brugia malayi | RNA binding protein | 0.0074 | 0.3239 | 1 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0021 | 0.0359 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0199 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0021 | 0.0359 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0074 | 0.3239 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0074 | 0.3239 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0074 | 0.3239 | 0.2987 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0021 | 0.0359 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0074 | 0.3239 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0199 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0021 | 0.0359 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0074 | 0.3239 | 0.2987 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0021 | 0.0359 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0021 | 0.0359 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0021 | 0.0359 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 1 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0021 | 0.0359 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0051 | 0.1944 | 0.5505 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0051 | 0.1944 | 0.1644 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0051 | 0.1944 | 0.1644 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0021 | 0.0359 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0051 | 0.1944 | 0.1644 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0051 | 0.1944 | 0.5505 |
Brugia malayi | TAR-binding protein | 0.0074 | 0.3239 | 1 |
Echinococcus multilocularis | geminin | 0.0199 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0051 | 0.1944 | 0.1644 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0021 | 0.0359 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0021 | 0.0359 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0021 | 0.0359 | 1 |
Trypanosoma brucei | unspecified product | 0.0021 | 0.0359 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0051 | 0.1944 | 0.1644 |
Giardia lamblia | DINP protein human, muc B family | 0.0021 | 0.0359 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0074 | 0.3239 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0051 | 0.1944 | 0.1644 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0021 | 0.0359 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 39 nM | Binding affinity towards human cloned Dopamine D3 receptor in CHO cells by [3H]-spiperone displacement. | ChEMBL. | No reference |
Ki (binding) | = 39 nM | Binding affinity towards human cloned Dopamine D3 receptor in CHO cells by [3H]-spiperone displacement. | ChEMBL. | No reference |
Ki (binding) | = 1027 nM | Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]-spiperone displacement. | ChEMBL. | No reference |
Ki (binding) | = 1027 nM | Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]-spiperone displacement. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.